



NVIDIA Healthcare and Life Sciences

Kimberly Powell, VP of Healthcare and Lifesciences

January 12, 2026

Except for the historical information contained herein, certain matters in this presentation including, but not limited to, statements as to: expectations with respect to the benefits, impact, performance, and availability of NVIDIA's products, services and technologies; expectations with respect to NVIDIA's third-party arrangements, including with its collaborators and partners; expectations with respect to technology developments; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections based on management's beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations.

Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA's reliance on third parties to manufacture, assemble, package and test NVIDIA's products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA's existing product and technologies; market acceptance of NVIDIA's products or NVIDIA's partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA's products or technologies when integrated into systems; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements within are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.


AI Scaling in Healthcare



AI Becomes
Agentic




AI Reaches the
Physical World




AI Learns Laws
of Nature

80% of Startups are Building on Open Models


Open Models Reach the Frontier




Open Reasoning AI Is the Backbone of Innovation



NVIDIA Leads Open Model Ecosystem





Agentic AI Has Become “Hirable”




\$4.9T Healthcare Industry Deploying AI 3x the U.S. Economy

Share of U.S. Business With Paid Commercial Licenses for AI Applications

— U.S. Economy — Healthcare (Overall) — Health Systems — Outpatient — Payers




Agents Are Multi Model, Multi Cloud, and Hybrid Cloud



Healthcare Agents



Clinical Conversation Agents



CONTEXTUAL REASONING ENGINE

- ✓ Clinical Conversations
- ✓ Prior Notes
- ✓ EHR Data
- ✓ Reimbursement Guidelines
- ✓ Payer-specific Rules
- ✓ Health System Rules & Templates
- ✓ Clinical Guidelines

CLINICAL NOTE

PATIENT SUMMARY (PVS)

History of Present Illness

The patient is a 53 year old male with atrial fibrillation, chronic kidney disease, diabetes, and hypertension. The patient presented with shortness of breath and chest tightness, also associated with dizziness that started about a week ago, with increased frequency, now on a near daily basis. The symptoms occur during strenuous activity like walking up stairs or going on a hike, and with lifting heavy objects. They deny palpitations, swelling in the ankles, lightheadedness or trouble lying flat, fevers, or chills. The patient has a history of childhood asthma, which was managed with an inhaler for a couple of years before resolving.

Physical Exam

CARDIOVASCULAR: Heart rate and rhythm are normal. S1 and S2 normal. No murmurs, rubs, or gallops.
CHEST: Auscultation reveals wheezing in the lower right lung.
ABDOMINAL: Soft, nontender, nondistended, no organomegaly. Normal bowel sounds.
EXTREMITIES: No abnormalities noted.

Assessment & Plan

Chronic kidney disease, stage 4
Chronic kidney disease stage 4 with GFR 20, severe impairment.
Managed with creatinine 2, no significant proteinuria.
- Continue current medications.



HE/HIM

COPY ALL

ABRIDGE





Health Agent Developer Platform



corti




Healthcare Workforce Agents





SPEECHMATICS

SULLY AI




Clinical Agents





Clinical Trial Agents



Disease Modeling Agents



Commercial Field Agents



Agentic Digital Health Ecosystem on NVIDIA

Patient Experience

ELLIPSIS
HEALTH

Epic

HUMANATE
AI healthcare workforce solutions

verily

Virtual Care

Hippocratic AI
— Do No Harm —

KeyCare

LORE

MAVEN

sword

therapyside

Clinician Experience

ABRIDGE

aidoc

Artisight

corti

Epic

HUMA

OpenEvidence

SPEECHMATICS

Patient Monitoring

ANDOR

Artisight

AvaSure

SafelyYou

Teton

Analytics Operations

ABRIDGE

innovaccer

IQVIA

Pangaea

SIMBIOSYS

verily

Clinical Operations

Epic

FUJITSU

InterSystems
Creative data technology

TELUS
Health

Clinical Development

ConcertAI


IQVIA

MAYO
CLINIC

Paradigm
Health

verily




Agents Accelerate Science





Science Agents





AI Co-Scientist



Scientific Superintelligence




Agents for Multi-Omics Drug Discovery




Agents Enter The Lab




Announcing Thermo Fisher Scientific Builds AI Infrastructure to Advance Scientific Instrumentation and Accelerate Lab Performance




Scaling Robot Intelligence for the Real World




Physical AI 3-Computer Platform




Industry Leaders Building on NVIDIA Isaac and GROOT



 **Multiply Labs**




 **HighRes**
biosolutions



 **Opentrons**

Cosmos
Physical AI



Isaac GROOT
Robotics

“NeurIPS 2025: Biology’s Transformer Moment”

Genetic Engineering & Biotechnology News, December 2025



“An AI Revolution in Drugmaking Is Under Way”

Economist, January 2026


“AI-Enabled Drug Discovery Reaches Clinical Milestone”

Nature Medicine, July 2025

Announcing New NVIDIA Clara Open Models




Proteina




RNAPro



CodonFM




KERMT



ReaSyn v2

Announcing The NVIDIA BioNeMo Platform

New open-source models, libraries, and training recipes



455K Synthetic Proteins



Data

CodonFM
KERMT
Proteina
ReaSyn v2^{NEW}
RNAPro^{NEW}




Models

cuEquivariance
nvMolKit^{NEW}
Parabricks
CUDA-X Data Science



Libraries and
Tools

BioNeMo Framework
BioNeMo Recipes^{NEW}



Training and
Customization

Virtual Screening
Protein Design




Blueprints

Expanding the BioNeMo Ecosystem to Enterprise Platforms


BCR BASECAMP
RESEARCH

natera™


tetrascience




Gene Therapy Design Platform




End-to-End Drug AI Platform



Scientific Data Discovery Platform





Growing NVIDIA BioNeMo Ecosystem

AI Drug Discovery

APHERIS

BCR BASECAMP RESEARCH

bi[o]hub

BIOVIA

Boltz

cādence

CERTARA

Chai Discovery

dyno

HelixAI

Latent Labs

open fold

Schrödinger

TERRAY

Data and Agents

Benchling

causalx

ConcertAI

CytoReason

Edison



IQVIA

LILA

OWKIN

Potato

tetrascience



Laboratories and Robots

Freenome


HighRes biosolutions

MultiplyLabs


natera

opentrons

ThermoFisher SCIENTIFIC



Lilly





AI Scaling in Healthcare

